Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial

Nikita Misella Hansen*, Anne Lise Kamper, Marianne Rix, Bo Feldt-Rasmussen, Jens Leipziger, Mads Vaarby Sørensen, Peder Berg, Arne Astrup, Louise Salomo

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

6 Citationer (Scopus)
9 Downloads (Pure)

Abstract

Background
Chronic kidney disease (CKD) leads to an accumulation of waste products and causes adverse cardiometabolic effects.

Objectives
We investigated the health effects of the New Nordic Renal Diet (NNRD), a novel meal pattern reduced in phosphorus, protein, and sodium.

Methods
A 26-wk randomized trial compared the NNRD with a habitual diet. The NNRD group received weekly home deliveries of food and recipes. Monthly study visits included fasting blood samples, 24-h urine samples, blood pressure, and anthropometric measurements. Intention-to-treat analysis used linear mixed-effects models.

Results
Sixty patients, mean estimated glomerular filtration rate (eGFR) 34 mL/min/1.73 m2 and body mass index of 25–27 kg/m2, were included and 58 completed. Metabolic syndrome was present in 53% (NNRD group) and 57% (control group). The NNRD group (n = 30) reduced their 24-h urine phosphorus excretion by 19% (−153 mg; 95% confidence interval [CI]: −210, −95), control group (n = 30) (no change), between-group difference −171 mg (95% CI: −233, −109; P < 0.001). Proteinuria was reduced by 39% in the NNRD group (−0.33 g/d; 95% CI: −0.47, −0.18), control group (no change), between-group difference −0.34 g/d (95% CI: −0.52, −0.17; P < 0.001). Plasma urea was reduced by −1.5 mmol/L in the NNRD group (95% CI: −2.1, −0.9), control group (no change), between-group difference −1.4 mmol/L (95% CI: −2.0, −0.7; P < 0.001). Systolic blood pressure fell by −5.2 mmHg in the NNRD group (95% CI: −8.4, −2.1), control group (no change), between-group difference −3.9 mmHg (95% CI; −7.6, −0.2; P = 0.04). The NNRD group lost −1.7 kg (95% CI: −2.6, −0.8), control group (no change), between-group difference −2.0 kg (95% CI: −3.0, −1.0; P < 0.001). There were no effects on eGFR during the 26-wk intervention.

Conclusion
NNRD in moderate CKD reduces phosphorus excretion, proteinuria, systolic blood pressure, and weight, mainly by reducing abdominal fat.

This trial was registered at clinicaltrials.gov as NCT04579315.
OriginalsprogEngelsk
BogserieAmerican Journal of Clinical Nutrition
Vol/bind118
Udgave nummer5
Sider (fra-til)1042-1054
Antal sider13
ISSN0002-9165
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This project has received financial funding from Augustinus Foundation (N/A), Gangsted Foundation (N/A), Helen and Ejnar Bjørnow Foundation (N/A), the Capital Region of Denmark’s Research Foundation (N/A), and the Danish Kidney Association (N/A).

Funding Information:
We thank all the participants for their contributions to this research. We thank Andreas Haltorp for his technical assistance in the laboratory and Lauren Rossi for editing the final manuscript. Finally, we thank Augustinus Foundation, Gangsted Foundation, Helen and Ejnar Bjørnow Foundation, the Capital Region of Denmark’s Research Foundation, and the Danish Kidney Association for funding the study.

Publisher Copyright:
© 2023 The Authors

Citationsformater